BioMarin Pharmaceutical Inc. (BMRN) EVP Sells $129,685.16 in Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Jeffrey Robert Ajer sold 1,436 shares of the stock in a transaction on Monday, June 11th. The stock was sold at an average price of $90.31, for a total value of $129,685.16. Following the completion of the transaction, the executive vice president now owns 50,135 shares in the company, valued at $4,527,691.85. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Jeffrey Robert Ajer also recently made the following trade(s):

  • On Monday, May 7th, Jeffrey Robert Ajer sold 309 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $85.96, for a total value of $26,561.64.
  • On Monday, April 2nd, Jeffrey Robert Ajer sold 2,119 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $80.12, for a total value of $169,774.28.
  • On Thursday, March 29th, Jeffrey Robert Ajer sold 1,537 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $79.69, for a total value of $122,483.53.
  • On Wednesday, March 21st, Jeffrey Robert Ajer sold 4,368 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $83.90, for a total value of $366,475.20.

Shares of BioMarin Pharmaceutical traded up $1.01, hitting $89.98, during trading hours on Thursday, Marketbeat Ratings reports. 1,232,188 shares of the company’s stock traded hands, compared to its average volume of 1,331,176. BioMarin Pharmaceutical Inc. has a 12-month low of $75.81 and a 12-month high of $100.03. The firm has a market cap of $15.87 billion, a PE ratio of -134.06 and a beta of 1.71. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.90 and a quick ratio of 2.29.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Wednesday, April 25th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.08). BioMarin Pharmaceutical had a negative net margin of 10.48% and a negative return on equity of 3.01%. The business had revenue of $373.45 million for the quarter, compared to analysts’ expectations of $348.73 million. During the same period in the prior year, the business earned $0.20 earnings per share. The company’s revenue for the quarter was up 22.9% compared to the same quarter last year. equities analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.12 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. Financial Gravity Companies Inc. purchased a new stake in shares of BioMarin Pharmaceutical during the 4th quarter valued at $112,000. Financial Gravity Wealth Inc. purchased a new stake in shares of BioMarin Pharmaceutical during the 1st quarter valued at $195,000. Redmile Group LLC purchased a new stake in shares of BioMarin Pharmaceutical during the 4th quarter valued at $223,000. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of BioMarin Pharmaceutical during the 4th quarter valued at $224,000. Finally, Gamco Investors INC. ET AL purchased a new stake in shares of BioMarin Pharmaceutical during the 4th quarter valued at $232,000.

A number of brokerages recently issued reports on BMRN. Sanford C. Bernstein cut their target price on BioMarin Pharmaceutical from $97.00 to $92.00 and set a “market perform” rating on the stock in a report on Monday, April 30th. ValuEngine upgraded BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a report on Monday, May 28th. Leerink Swann lowered their price target on BioMarin Pharmaceutical from $142.00 to $132.00 and set an “outperform” rating for the company in a research report on Friday, February 23rd. BidaskClub raised BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Tuesday, May 1st. Finally, Credit Suisse Group reissued a “buy” rating and issued a $113.00 price target on shares of BioMarin Pharmaceutical in a research report on Sunday, February 25th. One analyst has rated the stock with a sell rating, six have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $112.50.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply